<DOC>
	<DOCNO>NCT02444234</DOCNO>
	<brief_summary>The propose study design characterize pharmacokinetics intravenous oral tedizolid patient Cystic Fibrosis .</brief_summary>
	<brief_title>Pharmacokinetics Tedizolid Phosphate Cystic Fibrosis</brief_title>
	<detailed_description>Recent epidemiological study demonstrate presence methicillin-resistant Staphylococcus aureus ( MRSA ) airways patient CF associate rapid lung function decline high mortality . Tedizolid new antibiotic potent activity MRSA . Tedizolid currently FDA approve treatment skin soft tissue infection MRSA . The propose study design characterize pharmacokinetics intravenous oral tedizolid patient CF .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Torezolid</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Diagnosis CF base positive sweat chloride know CF mutation Age &gt; 17 year Able spontaneously expectorate sputum Any clinically significant laboratory abnormality Presence ongoing acute pulmonary exacerbation Pregnancy Serious past allergy linezolid tedizolid No alcohol , nicotine , caffeinecontaining product study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>